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ABSTRACT
CANNABINOIDS AND RETINAL FIBROTIC DISORDERS
Lucy Sloan
February 17th, 2022
Retinal fibrosis is detrimental to vision. Retinal pigment epithelial (RPE) cells
contribute to several retinal fibrotic diseases. Upon exposure to TGF-β, a key fibrotic
cytokine, RPE cells trans-differentiate to myofibroblasts marked by the integration of αSMA fibers into F-actin stress fibers, which confer strong contractility. Myofibroblasts
produce and contract the collagen-rich fibrotic scar and disrupt retinal architecture. In this
study, we investigated the in vitro effects of the putative endocannabinoid compound Noleoyl dopamine (OLDA) on TGF-β2 induced porcine RPE cell contraction and α-SMA
expression. Using an in vitro collagen matrix contraction assay, we found that OLDA
inhibited TGF-β2 induced contraction of collagen matrices by porcine RPE cells in a
concentration-dependent manner, with significant inhibition of contraction observed with
3 μM. OLDA did not significantly affect proliferation of porcine RPE cells. Further
investigations showed that treatment with 3 μM OLDA significantly decreased TGF-β2induced α-SMA incorporated stress fibers and total α-SMA protein expression. Taken
together these results indicate that OLDA has potential to inhibit TGF-β induced fibrosis
in the retina. Further studies are warranted to investigate the mechanism of action, other
fibrotic end points, as well as potential in vivo.
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CHAPTER I
INTRODUCTION
Cannabis sativa is a plant that contains over 150 phytocannabinoids (or plant
derived cannabinoids) including Δ9-tetrahydricannabinol (Δ9-THC), cannabidiol (CBD),
cannabinol (CBN), cannabigerol (CBG), and others [1-3]. Historically, cannabis first
appeared in Chinese medical texts around 2000 years BC and throughout history for a
wide variety of medical, cultural, and religious uses [4, 5]. In the Western medical world,
cannabis use first appeared in British medical texts in the early 1800’s. After initial
promising results in the medical world of the 19th century, cannabis became unpopular as
a result of anti-narcotics and anti-immigration campaigns in the early 20th century [6, 7].
Research in the late 1980’s and 1990’s identified the canonical cannabinoid
receptors CB1 and CB2. In subsequent years researchers developed ligands to act on
these receptors, allowing for investigation into their activities. Cannabinoids come in
various forms: from the cannabis plant as phytocannabinoids, synthetically produced as
synthetic cannabinoids, or endogenously produced known as endocannabinoids [8, 9].
These ligands can be further grouped into: classical agonists that act on CB1 and CB2
receptors like Δ9-THC and synthetic cannabinoid HU-210; nonclassical cannabinoids,
which are bicyclic and tricyclic analogues of Δ9-THC like CP 55,940 with dual CB1 and
CB2 agonist activity; the aminoalkylindole group of agonists includes WIN 55,212-2 and
are structurally distinct from the classical and nonclassical agonist groups with dual CB1
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and CB2 receptor activity; and lastly, the eicosanoid group of cannabinoids consisting of
the endocannabinoids 2-arachidnoyl glycerol (2-AG) and N-arachidonoylethanolamine
(AEA; anandamide) both of which have dual agonist activity at CB1 and CB2 receptors
[2, 10]. Cannabinoid compounds have highlighted the involvement of these two receptors
in modulating a plethora of physiological processes including homeostasis,
neurotransmission, wound healing, pathological conditions like cancer and inflammation,
and much more [8]. Moreover, these compounds have helped identify putative
cannabinoid receptors beyond CB1 and CB2.
ENDOCANNABINOID SYSTEM
Together, the cannabinoid receptors, endocannabinoids, and the biosynthetic and
catabolic enzymes of endocannabinoids make up the endocannabinoid system (ECS) [10,
11]. The ECS is now understood to be crucial in the development of the nervous system,
as well as the functioning mature nervous system [11].
Cannabinoid Receptors
The canonical receptors are the CB1 (CNR1) and CB2 (CNR2) receptors. The
CB1 receptor was originally identified in 1990 when it was discovered that Δ9-THC is
pharmacologically active at what was previously known as orphan G-protein coupled
receptor (GPCR) SKR6 [12]. A few years after the discovery of CB1 receptor, the CB2
receptor was identified in 1993 as the GPCR then known as CX5 [2]. Both receptors are
class A GPCRs that share 44% sequence homology [5]. CB1 receptors are primarily
expressed in the brain, most prominently in the cerebral cortex, hippocampus, basal
ganglia, cerebellum, and glia. The distribution of CB1 receptors in the central nervous
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system (CNS) reflects the role these receptors play in cognition, memory, and motor
function. However, CB1 receptors have also been found outside of the CNS in the spleen,
lung, liver, and skin. CB2 receptors are primarily expressed in the peripheral nervous
system, mainly in the cardiovascular, respiratory, reproductive, and immune systems, GI
tract, liver, bone, and microglia. Localization of these receptors similarly reflect the role
of CB2 receptors in modulating immune response through immune cell migration and
cytokine release both in central and peripheral nervous systems [2, 5, 11, 13].
Both the CB1 and CB2 receptors are GPCRs that signal through Gi/o proteins to
inhibit adenylyl cyclase and activate mitogen-activated protein kinases (MAPKs) such as
p38, JNK and ERK1/2 (p42/44). CB1 receptors acting through Gi/o are also able to
mediate activation of potassium channels and inhibition of calcium channels [2].
Furthermore, CB1 receptors can act in a ligand-specific manner to signal via through GS
proteins [5]. The mechanism behind the functional selectivity of these receptors is yet to
be elucidated, but it is clear that there is differential signaling at CB1 between the Gαi,
Gαo and Gαs coupled proteins. Moreover, there is functional selectivity between coupled
G proteins and β-arrestin recruitment that also appears to be ligand specific [5, 11].
The evolving research field of cannabinoids has identified a number of receptors
involved in the ECS other than CB1 and CB2. Most notably, several orphan GPCRs have
been identified as targets of a variety of cannabinoid ligands. For example, evidence
shows that GPR55 is activated endogenous, synthetic, and phyto- cannabinoids [2, 14].
There are multiple potential endogenous ligands of the GPR55 receptor, but the
endocannabinoid lysophosphatidylinositol (LPI) is reported to have the most consistent
activity GPR55. Synthetic cannabinoids like HU-210, a non-selective CB1/CB2 agonist,
3

and AM-251, a CB1 antagonist, are reported to activate GPR55 as well. Nevertheless,
this GPCR has low sequence homology with the canonical cannabinoid receptors, sharing
only 14% with CB1 and 8% with the CB2 receptor. [2, 5].
GPR3, GPR6, and GPR12 have been heavily investigated for their role in the ECS
because they share chromosomal positions and over 40% sequence homology to the CB1
and CB2 receptors. These orphan receptors are highly expressed in the CNS – most
prominently in the cerebellum, striatum, cerebral cortex, and hypothalamus, as well as in
other organs: mainly the eye, breast, liver, skin, stomach, ovaries, and testis. These
receptors are constitutively active however, the endogenous ligands for these receptors
are unknown and heavily debated with AEA and 2-AG having no reported activity [2, 15,
16]. Many cannabinoid ligands have been tested for activity at these receptors with few
positive hits, however CBD and cannabidivarin (CBDV) are reported to act as an inverse
agonist at all three receptors with slightly varying potencies [17-19].
GPR119 was identified in 2006 as a cannabinoid receptor that is activated by the
endocannabinoid AEA [20]. Later, 2-AG was discovered to act as a GPR119 agonist as
well. GPR119 is localized to the pancreas and the GI tract, and selectively expressed in
insulin-producing cells in the pancreas as well as some cells in the ileum and colon. It is
generally thought that GPR119 is involved in energy homeostasis with therapeutic
implications for type 2 diabetes, obesity, and other metabolic disorders [5, 21, 22].
Another class of receptors, the transient receptor potential (TRP) subfamily of
cation channels, has been heavily investigated for its involvement in the ECS. The TRP
receptors are involved in transducing a wide array of stimuli, particularly temperature,
pressure, pH, olfactive, taste, light, and pain stimuli as well as xenobiotic induced cell
4

signaling. Of note, cannabinoids have been shown to interact with TRPV1, TRPV2,
TRPV4, TRPM8 and TRPA1 receptors. There are six subfamilies, of which the vanilloid
(TRPV) subfamily has been the most promising ECS target thus far [23]. TRPV1,
specifically, is involved in transducing physical and chemical nociceptive signals, as well
as pathological processes like inflammation and cancer [24]. The first exogenous ligand
discovered at TRPV1 was capsaicin, however, it is now well established that
endocannabinoids AEA and 2-AG act as potent endogenous agonists at TRPV1 [2, 13].
Furthermore, synthetic cannabinoids like HU-210 and JWH-015 are shown to interact
with this receptor [2].
Lastly, the peroxisome proliferator-activated receptors (PPARs) are also shown to
be a target of endocannabinoids like AEA and 2-AG, phytocannabinoids like CBD and
Δ9-THC, and synthetic cannabinoids ajulemic acid and WIN 55,212. The three PPAR
isoforms are α, β, and γ and these receptors are notable targets in the treatment of type 2
diabetes [2]. PPARγ receptor agonists are also reported to have anti-inflammatory and
anti-fibrotic properties [25].
Endocannabinoids
Endocannabinoids are generally arachidonic acid related compounds that act
through the ECS [26]. The two best studied endocannabinoids are 2-AG and AEA.
However, there are four other recognized endocannabinoids including N-arachidonoyl
dopamine (NADA), 2-arachidonoyl glyceryl ether (2-AGE; noladin ether), Oarachidonoyl ethanolamine (OAE; virodhamine), and lysophosphatidylinositol (LPI) [5].
These compounds are produced and released on demand, however there is evidence
indicating that there may be transporters involved in facilitated transport.
5

Endocannabinoids also have reported activity within the ECS through potentiating other
related compounds in what is known as the “entourage effect” [26]. Thus, there are many
different roles these compounds play in physiological homeostasis [8, 27].
Biosynthetic, Transportation, and Metabolic Pathways
There are a number of different biosynthetic pathways involved in the production
of endocannabinoids. 2-AG is produced via diacylglycerol lipase (DAGL) and AEA is
produced via N-acyl phosphatidyl ethanolamine phospholipase D (NAPE-PLD).
Endocannabinoids are synthesized from phospholipids on the cytosolic side of the cell
membrane. Therefore to act extracellularly they must be able to leave the cell [11]. It is
generally thought that AEA and 2-AG are transported by the same endocannabinoid
membrane transporter. There is much debate on this area of endocannabinoid transport
with differing experimental results. Nevertheless, endocannabinoid membrane transporter
inhibitors have been developed as a way to alter AEA levels, and this transporter is a
known target of other endocannabinoids thought to play a role in regulating
endocannabinoid levels [5, 11]. In terms of metabolic enzymes, 2-AG is inactivated by
hydrolysis of the arachidonic acid group by monoacylglycerol (MAGL). AEA is
inactivated by fatty acid amino hydrolase (FAAH) mediated hydrolysis. Moreover, both
AEA and 2-AG are metabolized by cyclooxygenase 2 (COX-2) to form other bioactive
metabolites [11].
Conclusions
Researchers have developed pharmacotherapies that act on the different aspects of
the ECS with the intention of treating various diseases including neurodegenerative,
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neurobehavioral, metabolic, and immune system disorders [5, 11]. Targeting the ECS
could provide a novel axis of therapeutic treatments with unique benefits for many
diseases and disorders.
N-ACYL DOPAMINES
N-acyl dopamine compounds are endogenous ligands that are similar to the
endocannabinoid AEA in that the ethanolamide moiety is replaced with dopamine [22].
The hydrocarbon tail of N-acyl dopamine compounds is of varying degrees of length and
saturation (Figure 1), for example: N-palmitoyl dopamine (PALDA) has a saturated 16carbon side chain, N-oleoyl dopamine (OLDA) has an 18-carbon monounsaturated side
chain, and N-arachidonoyl dopamine (NADA) has a 20-carbon side-chain with 4 double
bonds [19]. The prototypical N-acyl dopamine compound is the endocannabinoid NADA
which is a potent CB1 and TRPV1 agonist [13, 22]. It was originally identified in the
bovine brain with highest concentrations in the striatum, cerebellum, hippocampus, and
substantia nigra and not identified outside of the brain. Moreover, the relative amount of
NADA in brain regions was similar to the density of TRPV1 receptors found [28]. OLDA
and PALDA were also identified in the bovine brain, however, far less is known about
these compounds compared to NADA [22, 29]. Further studies have confirmed the
presence of NADA, OLDA, and PALDA compounds in mammalian brains [30].
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Figure 1: Chemical structures of N-acyl dopamine compounds.
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N-acyl Dopamines Biosynthesis
Investigations into the biosynthesis of N-acyl dopamine compounds have focused
primarily on NADA, with few reports into the biosynthetic and catabolic routes of OLDA
and PALDA. There are two proposed pathways of NADA biosynthesis that are supported
by both in vitro and in vivo experimental data [13, 22, 28, 31]. The first proposed
pathway involves conjugation of arachidonic acid with dopamine via FAAH [13, 28, 32].
The second proposed pathway involves sequential modifications of precursor
compounds. The latter pathway mimics the biosynthesis of dopamine in that tyrosine
hydroxylase (TH) converts N-arachidonoyl-tyrosine to the precursor N-arachidonoylDOPA which is subsequently converted to NADA by aromatic amino acid decarboxylase
(AADC) [28, 30, 31]. In regard to the second proposed pathway, it has been suggested
that OLDA is synthesized through similar routes due to the similarity in structure to
NADA [21, 30, 33]. There are yet to be reports on the biosynthesis of PALDA.
N-acyl Dopamines Metabolism
Catabolic and metabolic pathways of N-acyl dopamines are similarly elusive,
however there are three proposed metabolic routes that have been investigated with
regard to NADA. The first involves hydrolysis of NADA to arachidonic acid and
dopamine by FAAH. The second route involves modification of the dopamine head
group by cytosolic catechol-O-methyltransferase (COMT) to form the less potent
compound O-methyl-NADA [13, 21, 22, 28, 31]. The last route involves metabolism by
microsomal cytochrome P450 (CYP450) to omega hydroxylated metabolites (HETE-DA)
that are shown to be active at recombinant TRPV1 receptors [13, 34]. Research from one
group determined through in vitro, ex vivo, and in vivo experiments that OLDA is
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metabolized to 3-methoxy-N-oleoyl-dopamine (3-Me-O-OLDA) by COMT similar to
NADA. Furthermore, it has been suggested that methylation of OLDA by COMT
enhances its activity at TRPV1 [35]. There have yet to be investigations into the
inactivation, metabolism, and breakdown of PALDA.
N-acyl Dopamines Molecular Signaling Targets
CB1: N-acyl dopamines are reported to have activity at the CB1 receptor,
however the affinity is modest and varies between NADA, OLDA, and PALDA. NADA
is reported to have the highest affinity for CB1 (Ki 250-500 nM), followed by OLDA
with moderate activity (Ki 1.6 μM , and lastly, PALDA with no reported activity at CB1
[13, 22, 30, 36]. NADA is reported to have a 40-fold selectivity for CB1 over CB2 and is
reported to be more potent and efficacious than AEA in calcium mobilization assays.
Moreover, NADA behaved as a typical CB1 agonist in vitro by inhibiting proliferation of
MCF-7 cancer cells and in vivo producing hypothermia, hypolocomotion, catalepsy, and
analgesia in mice [36].
TRPV1: NADA was originally discovered to be a potent agonist at human
TRPV1 receptors over-expressed in HEK-293 cells (EC50 ≈ 45 nM , less potent than
capsaicin (EC50 ≈ 24 nM [28]. Soon after, another study found that OLDA was a potent
agonist for TRPV1 (EC50 ≈ 36 nM with a reported potency similar to capsaicin (EC50 ≈
34 nM and more potent than ADA (EC50 ≈ 63 nM . PALDA was found to be inactive
at this receptor [30]. A later study, however, reported that PALDA was able to potentiate
the effects of NADA in HEK-293 cells overexpressing recombinant hTRPV1, suggesting
that ADA plays a role in the “entourage effect” [29].
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It has been suggested that the activity of N-acyl dopamines at TRPV1 is
dependent on the length and degree of saturation of the hydrocarbon tail (Figure 1). At
least one double bond is required for optimal access to the essential binding site of AEA
and capsaicin. For example, OLDA (C18:1) has the most potent agonist activity at
TRPV1, NADA (C20:4) has agonist activity that is intermediate and PALDA (C16:0) is
reported to be inactive at TRPV1 [13, 28-30].
FAAH: FAAH is a membrane bound enzyme that is responsible for hydrolyzing
bioactive lipid signaling molecules such as the endocannabinoids AEA and 2-AG. Early
research into N-acyl dopamines found that NADA is a competitive FAAH inhibitor,
indicating a role for NADA in regulating AEA through inhibiting its inactivation [13,
36]. However, another group found that neither NADA, OLDA, nor PALDA were able to
significantly inhibit FAAH in mouse N18TG2 cells [30]. Together, this evidence
suggests that N-acyl dopamines may play a physiological role in modulating AEA.
Endocannabinoid Membrane Transporter: The endocannabinoid membrane
transporter has long been proposed and heavily debated as a mechanism of rapid uptake
of AEA. Research indicates that NADA is rapidly taken up by the endocannabinoid
membrane transporter in C6 glioma cells leading to the inactivation of this transporter.
Similar results were found in RBL-2H3 cells with OLDA and PALDA at high
concentrations [13, 28]. Moreover, researchers discovered that OLDA is able to inhibit
AEA uptake in mouse cells in vitro, but PALDA failed to show the same effect [30].
Therefore, AEA cellular uptake may be regulated by N-acyl dopamine compounds.
Other GPCRS: GPR119 is a GαS receptor that is found in pancreatic islet cells
and the gut. Research shows that OLDA is a potent GPR119 agonist that induces insulin
11

secretion in vitro and increases glucose tolerance in vivo. This research suggests that
OLDA may be the endogenous ligand for GPR119 [21]. Moreover, the activity of OLDA
at GPR119 is dependent on the dopamine head group and hydrocarbon tail as shown by
no effect with a tyrosine head group (N-oleoyl tyrosine) or with a different side chain
(NADA) [21, 22, 37]. More recently, NADA, OLDA, and PALDA were all found to have
inverse agonist activity at GPR6 that was concentration dependent. Structure activity
relationship revealed that both the N-acyl side chain and the dopamine head group were
required for activity at GPR6 [19].
Voltage gated calcium channels: There are a number of N-acyl amine compounds
that are reported to have activity at N-Type calcium channels, however NADA is not
among them [22]. AEA is an antagonist at T-type calcium channels and investigations
with NADA and OLDA found both compounds potently inhibit human recombinant
CaV3 channels to an equal or greater degree than AEA. However, the unsaturated
PALDA had no appreciable effect [38]. Many more studies will need to be completed to
further understand the kinetics of N-acyl dopamine compounds at these receptors, as well
as determine the physiological role of these compounds in regulating intracellular
calcium levels.
Dopamine receptors: Between the N-acyl dopamine compounds, there are varying
degrees of interaction with the dopamine receptors. Originally, NADA was reported to
have low affinity for the dopamine receptors by failing to displace high affinity D1 and
D2 receptor ligands [36]. OLDA is reported to affect locomotor activity in a
dopaminergic dependent manner. This was exemplified when systemic administration of
OLDA caused an increase in locomotor activity, which was blocked by the D2 antagonist
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haloperidol [39]. Moreover, OLDA is reported to cross the blood brain barrier, a crucial
trait to affect CNS function [40]. There is yet to be research investigating the interaction
of PALDA at any dopamine receptors.
Conclusions
Research is beginning to highlight the potential therapeutic applications of N-acyl
dopamines, as well as further understand their role in physiology and disease. The
receptors that these compounds act on may provide innovative therapeutic approaches to
modulating the ECS and various pathological conditions such as neurologic and
metabolic disorders and diseases marked by inflammation.
CANNABINOIDS AND FIBROSIS
Fibrosis is a leading cause of disease in the US and chronic diseases commonly
present with excessive scarring, a hallmark of fibrosis. During normal wound healing
processes, myofibroblasts accumulate at active inflammation sites to close wounds via
contraction, acting as repair cells to produce and re-organize extracellular matrix (ECM)
after injury [41]. Myofibroblasts are mesenchymal cells marked by the presence of αsmooth muscle actin (α-SMA) and stress fibers. These cells are primarily responsible for
the production and secretion of cytokines and ECM components like collagen during
wound healing [42]. Myofibroblasts disappear via apoptotic pathways following reepithelialization of the injury, however under pathological conditions, myofibroblasts
accumulate and undergo excessive fibrogenesis resulting in scars with high collagen
content. These scars disrupt and alter tissue function and tissue microenvironment,
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eventually causing organ dysfunction. In cases of chronic fibrotic scarring, organ failure
can occur [41, 42].
After epithelial cell injury, loss of contact inhibition induces expression of
epithelial-to-mesenchymal transition (EMT) transcription factors like Snail, Slug, Zeb1
and Twist1 to aid in wound healing [42, 43]. These transcription factors suppress
epithelial cell markers and promote the mesenchymal phenotype and myofibroblast
proliferation. Transforming growth factor β (TGF-β) is a key fibrotic cytokine that is
produced by inflammatory cells, fibroblasts, or epithelial cells and activates both the
canonical TGF-β signaling pathway through Smad2/3, and the non-canonical pathway
through MAPKs (ERK1/2, JNK, p38/MAPK14) [41]. Other signaling pathways activated
by biochemical and biophysical properties of the ECM accompanying EMT include the
focal adhesion kinase (FAK) signaling pathway, the β-catenin/Wnt signaling pathway,
and the Rho/ROCK/MRTF-A pathway [44, 45].
Endocannabinoid Changes Associated with Fibrosis
Research has shown that in fibrotic tissues the ECS is dysregulated with mounting
evidence showing that CB2 activation and CB1 inhibition suppresses inflammation and
myofibroblast conversion, preventing the fibrotic process [46-53]. Specifically, CB1
receptors were found to be upregulated in experimental models of renal fibrosis [14, 54]
and liver fibrosis [49, 50]. In the latter, CB1 antagonism caused a decrease in
phosphorylation of ERK and Akt associated with reduced myofibroblast accumulation
and decreased liver fibrosis [49]. Another group showed that ablation of CB1 receptors
using RNAi decreased expression of TGF-β in vivo and inhibited experimental liver
injury. It was reported that these effects were modulated through the Smad signaling
14

pathway [50]. Furthermore, CB1 receptor activation was shown to enhance bleomycin
(BLM) induced skin fibrosis [55]. Taken together, there is increasing evidence indicating
that the CB1 receptor is involved in fibrogenesis and that pharmacological inhibition of
CB1 receptors provides a novel therapeutic treatment in preventing the progression of
fibrotic disorders.
In regard to the CB2 receptor, it is primarily expressed in the immune cells of the
peripheral nervous system and its activation is associated with anti-inflammatory and
immuno-modulatory effects [47]. CB2 receptors are reported to be upregulated in the
cirrhotic liver, especially in fibrogenic hepatic cells and activation of CB2 exerted strong
anti-fibrotic effects [52]. Investigations into skin wound healing and dermal fibrosis
found that CB2 activation decreased neutrophil and macrophage infiltration, decreased
classic markers of inflammation and fibrosis, and reduced fibroblast accumulation [47].
Furthermore, genetic CB2 inactivation (CB2 -/-) in mice produced an increase in BLMinduced dermal fibrosis and leukocyte infiltration in vivo [56]. Lastly, Fu et al. (2017)
found that CB2 receptors were upregulated in a model of BLM induced pulmonary
fibrosis. They reported that CB2 activation via synthetic cannabinoid JWH-133 caused a
decrease in TGF-β1, collagen I, and α-SMA expression in vitro. They went on to report
that JWH-133 also reduced BLM-induced pulmonary fibrosis in vivo, showing a decrease
in overall pulmonary density and inflammation compared to control [46]. Therefore,
these two receptors are highlighted as therapeutic targets in the treatment of fibrosis.
Lastly, the ECS itself has been implicated in the fibrotic process. In a model of
renal fibrosis induced by unilateral ureteral obstruction, 2-AG levels were increased [14]
and both 2-AG and AEA were increased with chronic liver injury [53]. Research has
15

shown that AEA is noted to be involved in the regulation of fibrogenic cells independent
of CB1 and CB2 receptors [49]. Furthermore, FAAH plays a potential role in fibrosis
through modulating the synthesis and breakdown of endocannabinoids involved in
fibrogenesis. In a model of BLM induced systemic fibrosis, FAAH was found to be
negatively associated with an increase in endocannabinoids. It was confirmed that
pharmacological inhibition of FAAH increased BLM-induced fibrosis [57].
Therefore, it appears the ECS is dysregulated in fibrotic states. Current research
indicates that cannabinoids acting on the ECS could provide novel therapeutic treatments
to a variety of fibrotic conditions in organs including skin [25, 47, 48, 58], liver [49, 50,
52, 53], heart [59], kidney [14, 54], and lung [25, 46]. Moreover, the reported antiinflammatory, anti-nociceptive, and neuroprotective effects associated with cannabinoids
could provide additional therapeutic value in treating these disorders.
Retinal Fibrotic Conditions
Ocular injury or pathological conditions like diabetic retinopathy (DR) and agerelated macular degeneration (AMD) can result in fibrosis in the retina and subsequent
loss of visual acuity [60]. The eye is an intricately organized organ that can be divided
into two main components: the anterior segment which includes the cornea, the lens, and
iris, and the posterior segment made of the vitreous, choroid, and retina. Undisturbed
architecture is required for visual acuity. The retina is considered part of the central
nervous system and is made up of layers – the photoreceptors lie on top of the retinal
pigmental epithelial (RPE) cell layer, which are on top of a collagenous basement
membrane, sitting atop the blood vessel-rich choroids [60-62]. The vitreous is a
viscoelastic substance made up primarily of water, collagen, and hyaluronic acid. It can
16

serve as a scaffold for scar formation on the retinal surface which is associated with
several fibrotic retinal complications such as proliferative diabetic retinopathy (PDR),
proliferative vitreoretinopathy (PVR), and retinopathy of prematurity (ROP) [60, 62].
The ECS is intertwined with the mammalian eye as seen by the presence of
biosynthetic and metabolic enzymes, endocannabinoids (2-AG and AEA), and canonical
and non-canonical cannabinoid receptors in the retina [61, 63-65]. CB1 receptors are
present throughout the retina [61, 64, 66]. However, the localization of CB2 receptors is
contradictory. One report did not detect CB2 receptors in the [66] while another reported
their presence in human RPE cells [67] and in Müller glia cells in monkey retina [68].
RPE cell dysfunction is common in retinopathies such AMD and degenerative
retinopathies [62]. In diabetes, hyperglycemia is associated with ECS dysregulation
throughout the body, but also specific to RPE cells [69-71]. Recently, a number of
investigations have highlighted ECS changes and therapeutic effects of ECS modulation
in experimental models of retinal fibrosis in vivo (Table 1).
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Table 1: Effects of cannabinoids on experimental retinal fibrotic conditions in vivo
Ocular Condition
Uveitis

Model
Autoimmune
uveoretinitis

Treatment
JWH-133
• CB2
selective
agonist

Diabetic
Retinopathy (DR)

Streptozotocin- CB1-/induced DR
SR141716
• CB1
selective
antagonist

Proliferative
vitreoretinopathy
(PVR)

Dispaseinduced PVR

HU308
• CB2 agonist
AM630
• CB2
antagonist
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Effects
• Improved clinical scores
• ↓I Fγ, T Fα, IL-10,
IL-6, CCL2
• ↓ Leukocyte trafficking
in retina
• Completely prevented
retinal cell death
• Prevented retinal cell
death
• ↓ Oxidative and
nitrative stress
• ↓ FκB, ICAM-1,
VCAM-1
• ↓ p38 and J K
activation
• Improved clinical scores
• ↓ microglia activation,
accumulation
• Worsened clinical
scores
• ↑ microglia activation

Refs
[72]

[73]

[74]

Uveitis is an ocular condition that is marked by inflammation in the eye, including
in the retina [75]. It has been suggested that cannabinoid modulation of inflammation
could provide a therapeutic treatment for this disease [61]. One group used an in vivo
model of autoimmune-induced uveoretinitis to investigate the effects of the synthetic
CB2 selective agonist JWH-133 (Table 1). They found that CB2 activation reduced both
inflammatory cell infiltration and retinal structural changes while improving clinical and
histopathological scores. They noted that JWH-133 reduced production of cytokines like
IF , T Fα, IL-6 and IL-10 and attributed the anti-inflammatory effects to the action of
JWH-133 on lymphocytes [61, 72].
DR and proliferative diabetic retinopathy (PDR) are retinal disorders associated
with diabetes that can result in retinal fibrotic scar formation through chronic
inflammation and neovascularization [60, 76]. It is one of the leading cause of vision loss
in Americans under the age of 65. Pathological neovascularization often induces
hemorrhage which is also involved in the pathogenesis of PDR as well as PVR, ROP, and
one form of AMD – wet AMD [60].
Specific to DR, hyperglycemia and associated dysregulated levels of 2-AG and
AEA promote retinal neurodegeneration via altering vascular permeability and disrupting
mitochondrial function. Activation of CB1 receptors can induce reactive oxygen species
(ROS) production through disruption of mitochondrial function [69]. Furthermore, RPE
cells exposed to hyperglycemic conditions were shown to downregulate FAAH
expression and upregulate CB1 receptor expression in vitro. Over-expression of FAAH
and CB1 inhibition significantly increased RPE cell viability in this study [77]. In an in
vivo investigation using a model of DR one group found that CB1 receptor blockade
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inhibited ROS formation, Müller glia cell activation, and pro-inflammatory cytokine
release. Meanwhile, CB1 receptor activation was shown to exacerbate retinal fibrosis in
this model (Table 1) [73].
Lastly, PVR is a fibrotic complication associated with retinal detachment. It is
marked by a chronic inflammatory wound healing response that results in an epiretinal
fibrotic scar that can become contractile to eventually cause traction retinal detachment
(TRD) [43, 74]. One study found that CB2 activation decreased PVR scores in an
experimental model of dispase-induced PVR (Table 1) [74].
Conclusions
Taken together, the evidence presented here highlights the involvement of the
ECS in diseases like chronic inflammatory disorders, diabetes, and fibrosis. Many fibrotic
conditions are marked by a dysregulated ECS, and mounting evidence highlights this
system as crucial in the pathogenesis of these conditions. More specifically, recent
research has highlighted the ECS as an innovative and novel therapeutic target in the
treatment of retinal fibrotic disorders caused by injury or associated with conditions like
DR, PVR, and uveitis.
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CHAPTER II
EFFECTS OF N-OLEOYL DOPAMINE (OLDA) ON PORCINE RETINAL PIGMENT
EPITHELIAL CELLS
Introduction
Retinal fibrosis associated with conditions like PVR, AMD, and diabetes is
detrimental to vision. These conditions are marked by the presence of an epiretinal
membrane (ERM) that is essentially a fibrotic scar on the surface of the retina. ERMs
develop in response to retinal injury and/or retinal detachment surgery leading to an
aberrant wound healing response [75, 78]. These scars can eventually contract causing
traction retinal detachment (TRD) associated with vision loss. The primary objective of
treating these ocular conditions is to prevent the formation of ERMs. Once they have
formed, however, the therapeutic objective is to prevent the contraction of these fibrotic
scars [79]. Currently, there are no treatments available for the management of ERMs with
the exception of surgery or intravitreal anti-VEGF treatments [78].
ERMs develop idiopathically or secondarily due to diabetes, PVR, retinal
damage, macular degeneration, or ocular trauma [75, 78]. Investigations into the cell
types in ERMs have identified migrated RPE cells, (Müller) glial cells, fibrocytes,
fibrous-astrocytes, fibroblasts and myofibroblasts [43, 74, 75, 78-81]. RPE cells are
shown to undergo epithelial-to-mesenchymal transition (EMT) to a migratory and
invasive mesenchymal state upon injury and loss of cell-cell contact [82]. These
mesenchymal RPE cells stain positive for both cytokeratin: an epithelial cell marker and
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α-SMA: a myofibroblast cell marker [43]. TGF-β is a cytokine that is widely considered a
master regulator of the fibrotic process and plays a critical role in the formation of ERMs
both idiopathically and secondarily [75, 78]. TGF-β signals via Smad and non-Smad
pathways to promote the myofibroblast phenotype and suppress the epithelial phenotype
in RPE cells, contributing to the formation and contraction of ERMs [43]. Furthermore,
increased production of TGF-β is associated with injury and inflammation that is
common with fibrotic retinal conditions [83].
Cannabinoids are compounds that act on the CB1 and CB2 receptors, as well as
other GPCRs. There are endogenously produced cannabinoid compounds termed
endocannabinoids that are enzymatically synthesized and degraded in vivo. Together, the
receptors, enzymes, and endocannabinoids comprise the endocannabinoid system (ECS)
[8, 11]. The ECS has been highlighted as a therapeutic target in the treatment of fibrosis
due to mounting experimental evidence in different models of fibrosis, both in vivo and in
vitro, in a variety of organs [14, 25, 46-48, 50, 51, 53, 54, 58]. This includes the ability of
cannabinoids to regulate TGF-β levels and TGF-β signaling cascades [14, 46-48].
More recently, the ECS has been highlighted as a target for the treatment of
various ocular fibrotic disorders such as proliferative vitreoretinopathy (PVR), diabetic
retinopathy (DR), and others [65, 70-73, 77, 84]. In various in vivo models of retinal
fibrosis, CB1 inhibition or CB2 activation was found be therapeutically beneficial in
reducing clinical scores and/or inflammation (Table 1) [72-74]. Therefore, the ECS is an
innovative and novel therapeutic target in the treatment and prevention of ERMs
secondary to conditions like chronic inflammation, diabetes, and ocular injury.
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Putative endocannabinoid N-oleoyl dopamine (OLDA) is structurally related to
the endocannabinoid N-arachidonoyl dopamine (NADA), a potent CB1 agonist with
activity at TRPV1. OLDA is reported to have weak or no activity with CB1, however is a
potent TRPV1 and GPR119 agonist [13, 22]. One previous report suggested anti-fibrotic
potential for these compounds when they found that at 10 μM, OLDA significantly
downregulated TGF-β induced collagen expression in renal tubular epithelial cells in
vitro [14].
In this study, we investigated the potential of OLDA at different concentrations to
inhibit TGF-β2 induced contraction of dedifferentiated porcine RPE cells in vitro using a
3D hydrated collagen matrix contraction assay. In the presence of TGF-β,
dedifferentiated cells will transform to myofibroblasts and exert strong contractility in
collagen matrix contraction assays [85]. We found that OLDA significantly inhibited
TGF-β2 induced contraction of collagen matrices by porcine RPE cells in vitro in a
concentration-dependent manner. Moreover, OLDA downregulated the myofibroblast
cell marker α-SMA at 3μM. Taken together, our results suggest that OLDA has potential
in treating retinal fibrotic conditions associated with conditions like diabetes, retinal
injury and PVR, and AMD.
Materials and methods
Porcine eyes: Primary cultures of porcine RPE cells were isolated from adult
porcine eyes kindly donated by Swift Meat Packing Co. (Louisville, KY) based on
previously reported methods [81, 86]. Porcine RPE cell isolation: Briefly, following
sterilization of the eye using 5% betadine and washed in PBS, posterior eye cups were
prepared by removal of the anterior segment using surgical scissors. Posterior eyecups
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were then incubated in 0.5% dispase/5% FBS DMEM/PBS solution for 1 hour at 36 °C.
RPE sheets were gently removed from the eyecup using PBS, washed, collected, and
grown in Dulbecco’s modified Eagle’s medium (DMEM; VWR; Radnor, PA)
supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO), 100 IU/mL penicillin, 100
μg/mL streptomycin, and 10uM of ROCK inhibitor Y27632 for primary culture. Cell
culture: RPE cells were cultured in 10% FBS DMEM, routinely passaged using 0.05%
Trypsin-EDTA utilized between passages 3 and 4 for contraction assays,
immunocytochemical staining, and western blot analysis.
Contraction assay: Analysis of collagen gel matrix contraction mediated by RPE
cells at passage 3 and/or 4 was performed using established methods [81, 85-87].
Dedifferentiated RPE cells were used in vitro to model the formation and contraction of
epiretinal membranes on solidified neutralized type I collagen (Fujifilm Wako,
Richmond, VA). Neutralized type I collagen was added (0.4 mL) to each well in a 24well plate and allowed to solidify. RPE cells in 2.5% FBS-DMEM were added to each
well at 1.0 x 105 cells per well. After 4 hours, cells were treated with ligands and then 15
minutes later treated with TGF-β2 (10 ng/mL). After 72 hours, gels were gently released
from the wells and allowed to contract for 4 hours before photographed to measure
contraction using Photoshop CS6 software version 22.5.1 (Adobe Systems, San Jose,
CA). Results are mean ± SEM from 2 different samples for each condition from 2
different batches.
BrdU assay: Cell proliferation was measured with a Bromodeoxyuridine (BrdU)
cell proliferation assay kit (Cell Signaling Technology; Danvers, MA). RPE cells were
plated at a density of 5.0 x 103 in a 96-well plate and cultured in 10% FBS-DMEM for 3
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days in the presence of TGF-β2 (10 ng/mL and OLDA (3 μM or vehicle (ethanol). After
3 days, cells were incubated using the BrdU kit. BrdU was incubated with cells for 4
hours to allow for incorporation and then detected with primary and secondary antibody
solutions with wash steps according to manufacturer’s protocol. Using a plate reader,
spectrophotometric detection at 450 nm was used to measure BrdU incorporation. Results
are mean ± SEM from 3 different experiments with 3 different batches of cells and
replicates of 4 or 5; p <0.05 was considered significant.
Western Blot: Collagen gels with attached RPE cells from contraction assays were
prepared for western blot using lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1
mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM βglycerophosphate, 1 mM Na3VO4, and 1 μg/mL leupeptin , sonicated, and subject to
centrifugation to remove collagen. Samples were reduced for SDS-PAGE with DTT (0.1
M) and 4x loading dye before being heated at 70 ºC and centrifuged at 12,000 rpm for 1
minute. Subsequently, proteins were resolved on a 10% SDS–polyacrylamide gel using a
minigel electrophoresis system (Invitrogen; Waltham, MA) and transferred onto a
nitrocellulose membrane. The nitrocellulose membranes were blocked with 5% nonfat
dried milk in TBS-T buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 0.3% Tween
20) and incubated overnight at 4°C with the antibody of choice (anti-α-SMA and antiGAPDH; Cell Signaling Technology, Danvers, MA). The membranes were then washed
three times for 5 minutes each time with TBS-T buffer and incubated with secondary
antibody for 2 hours at room temperature. The membranes were again washed three times
with TBS-T buffer for five minutes each time and the antibody-recognized protein bands
were visualized by chemiluminescence substrates from Thermo Fisher Scientific
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(Waltham, MA) and quantified using NIH image J. Results are mean ± SEM from 2
different experiments and normalized to control with p <0.05 considered significant.
Immunocytochemistry: RPE cells were cultured in a 48-well plate on collagen
(0.15 mL) and fixed using 4% paraformaldehyde for 10 minutes. After three washes in
PBS, fixed collagen gels with cells attached were blocked in 5% serum with 0.3% Triton
X-100/5% BSA and incubated in primary antibodies (against α-SMA) in 1% BSA-PBS at
4° C overnight. Samples were then washed in 0.1% Triton X-100/PBS three times and
treated with secondary antibodies in 1% BSA-PBS for 1 hour at room temperature before
washed twice more. Samples were mounted with Vectashield with DAPI (H-1200,
Vector Laboratories, Burlingame, CA) and photographed using an inverted fluorescence
microscope (Axiovert 200; Zeiss Microimaging, Thornwood, NY) with a digital camera
(AxioCam; Zeiss microimaging).
Statistical analysis: GraphPad Prism (GraphPad Software; San Diego, CA) was
used for statistical analysis, with p-values <0.05 considered significant. One-way
ANOVA was used for analyses of collagen matrix contraction and BrdU proliferation.
Student’s t-test was used for analyses of immunoblot assays.
Results
Effect of N-oleoyl dopamine on RPE cell mediated matrix contraction.
Dedifferentiated primary RPE cells were used to examine the effects of OLDA, an
endogenous endocannabinoid-like compound, on matrix contraction of collagen gels in
vitro. Upon treatment with TGF-β2, RPE cells potently contracted the collagen gel matrix
(Figure 2A and 2D). However, treatment with 10 μM OLDA prevented RPE mediated
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collagen matrix contraction (Figure 2B). The effect of OLDA on matrix contraction by
RPE cells was concentration-dependent (Figure 2B and 2C). Data analysis showed that 3
μM OLDA significantly inhibited RPE cell matrix contraction and that these matrices
were similar to those not treated with TGF-β2 (p<0.05; Figure 2D).
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A

B

C

D

Figure 2: OLDA inhibited collagen matrix contraction by dedifferentiated porcine
RPE cells. Primary cultured porcine RPE cells were plated on hydrated collagen gel
matrices and treated with ligands and TGF-β2 for 72 hours. Gels were released from the
plate and allowed to contract for 4 hours. A. Representative images of RPE cells on
collagen gels treated with or without TGF-β2. B. Representative images showing that
OLDA inhibited RPE mediated matrix contraction in a concentration dependent manner.
C. OLDA inhibited collagen matrix contraction by porcine RPE cells compared to TGFβ2 + vehicle control in a concentration dependent manner. Data is presented as mean ±
SEM (n=2). D. 3 μM OLDA significantly inhibited RPE cell mediated collagen matrix
contraction compared to vehicle (*p < 0.05).
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Effects of N-oleoyl dopamine on α-SMA expression in RPE cells. We then went on
to investigate the effect of OLDA on the expression of α-SMA, a myofibroblast cell
marker [85]. α-SMA is shown to be upregulated in dedifferentiated RPE cells involved in
ERM formation and contraction [43]. TGF-β2 also induces expression of α-SMA in vitro
[82]. Using immunocytochemistry to stain against α-SMA, we found that treatment with
3 μM OLDA strongly downregulated cellular expression of α-SMA in stress fibers
compared to vehicle (Figure 3). Moreover, OLDA appeared to induce a morphological
change in dedifferentiated RPE cells to a more cobblestone-epithelial phenotype rather
than a mesenchymal phenotype (Figure 3). We confirmed these results using western blot
(Figure 4A) and found that 3 μM OLDA significantly downregulated cellular expression
of α-SMA in vitro (p<0.05; Figure 4B).
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Figure 3: OLDA downregulated TGF-β2 induced α-SMA expression. Representative
images of primary cultured porcine RPE cells plated on hydrated collagen gels and
treated with 3 μM OLDA and TGF-β2 (10 ng/mL for 72 hours (n=2). Hydrated collagen
gels were fixed and immunostained for DAPI (blue), F-actin (red , and α-SMA (green).
Treatment with 3μM OLDA downregulated α-SMA expression in F-actin stress fibers
and induced morphological changes.
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B

Figure 4: OLDA inhibited TGF-β2 induced cellular expression of α-SMA in porcine
RPE cells. Cells were plated on hydrated collagen gels and treated with ligands and
TGF-β2 for 72 hours, released from the plate, and allowed to contract for 4 hours. Gels
were collected, cells lysed, resolved with SDS-PAGE, and immunoblotted for expression
of α-SMA and GAPDH. A: Representative blot image (n=2). B. NIH Image J
quantification of western blots. Treatment with 3 μM OLDA significantly decreased αSMA expression in porcine RPE cells (Student’s t-test; *p < 0.05). Data are presented as
mean ± SEM.
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N-oleoyl dopamine does not affect proliferation. Lastly, to confirm therapeutic
viability of OLDA, we wanted to investigate its effects on cell proliferation. One group
previously reported that high concentrations of NADA and AEA potently inhibited breast
cancer cell proliferation in vitro [36, 88]. Using a BrdU re-uptake assay, we found that 3
μM OLDA did not significantly affect proliferation of RPE cells compared to vehicle
(Figure 5; p>0.05).
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Figure 5: OLDA did not affect proliferation in porcine RPE cells. Primary cultured
porcine RPE cells were treated with ligands and TGF-β2 for 72 hours. Neither OLDA (3
μM significantly affected proliferation of porcine RPE cells compared to vehicle or
control treatment (p < 0.05). Y axis normalized to TGF-β2 + vehicle control, data are
presented as mean ± SEM (n=3).
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Discussion
Retinal fibrotic conditions associated with chronic inflammation and an aberrant
wound healing response are associated with diseases like diabetes, AMD, and retinal
injury [60]. Currently, there are very few effective therapies for treating or preventing the
formation of retinal fibrotic scars [62]. This is the first study to show that OLDA
inhibited TGF-β2 induced contraction of collagen matrices by porcine RPE cells and that
OLDA downregulated TGF-β2 induced α-SMA expression.
Previous investigations into the formation of ERMs found that RPE cells undergo
EMT to a migratory and invasive phenotype to contribute to the wound healing process.
These RPE cells are marked by both cytokeratin, an epithelial cell marker, and α-SMA, a
myofibroblast marker [43]. TGF-β treatment induces RPE cells to contract type I
collagen gels in vitro [87, 89, 90]. In the vitreous of human eyes afflicted with PVR,
TGF-β levels are noted to be three times higher compared to healthy eyes and TGF-β2
was found to be the primary isoform in retinas from PVR patients [75, 91, 92]. We found
that the N-acyl dopamine compound OLDA, a putative endocannabinoid, inhibited
dedifferentiated porcine RPE cell contraction of collagen matrices induced by TGF-β2 in
a concentration-dependent manner (Figure 2).
There is evidence that other cannabinoids are able to modulate the TGF-β
signaling cascade. TGF-β signals through Smad and non-Smad signaling pathways like
MAPKs and mTOR to induce transcription of myofibroblast genes like α-SMA, collagen,
and fibronectin and suppressing epithelial genes like E-cadherin [93]. CB1 inhibition
with synthetic cannabinoid AM-251 decreased TGF-β induced expression of collagen and
α-SMA in renal tubular epithelial cells. Upon further analysis, the effects of CB1
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inhibition on TGF-β signaling were via inhibition of downstream TGF-β signaling
cascades like Snail, MAPK p38, and Smad2/3 signaling [14]. This same study found that
OLDA downregulated TGF-β induced collagen expression in renal tubular epithelial cells
associated with fibrosis at 10 μM [14]. In the present study, we found that at 3 μM,
OLDA treatment significantly downregulated TGF-β2 induced expression of α-SMA
(Figure 4) and induced a morphological change to the cells, appearing less mesenchymal
(Figure 3). Taken together, this data shows that OLDA has a potential role in regulating
TGF-β-induced signaling.
Lastly, previous reports have found that high concentrations of NADA and AEA
are reported to potently inhibit breast cancer cell proliferation [36, 88]. However, using a
BrdU proliferation assay, we found that at 3 μM OLDA did not significantly affect cell
proliferation induced by TGF-β2 (Figure 5 . The discrepancy in reports may have to do
with weak activity at CB1 by OLDA compared to NADA or perhaps cell type
differences.
The ECS has been highlighted as a potential therapeutic target in the treatment of
retinal damage of various sources (Table 1). Specific to RPE cells, hyperglycemia
induced a decrease in FAAH expression and an increase in CB1 receptor expression in
ARPE-19 cells. This group showed that FAAH over-expression and treatment with AM251, a CB1 antagonist, prevented hyperglycemia-induced ROS production and apoptosis
[77]. Taken together, this evidence highlights the ECS as a novel therapeutic target in the
treatment of retinal fibrotic conditions associated with diabetes, oxidative stress,
ischemia, and inflammation.
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N-acyl dopamines are potentially able to modulate the ECS via FAAH. One
report found that NADA inhibits FAAH with an IC50 of 23 μM [36], however another
report found no interaction between NADA, OLDA, or PALDA and FAAH [30].
Nevertheless, the latter report by Chu et al. 2003 found that OLDA and NADA inhibited
AEA transport with moderate affinity (Ki = 14.1 μM OLDA [30]. Therefore, it is
possible that OLDA is able to modulate a dysregulated ECS through blocking activity of
overexpressed endocannabinoids like 2-AG and AEA.
While investigations into the activity of NADA at CB1 show it is a potent agonist
with high affinity (Ki 250-500 nM) [30, 36], OLDA is reported to be a weak agonist (Ki
1.6 μM [13, 30, 36]. At TRPV1 however, OLDA is reported to be a potent agonist, more
potent than NADA [30]. The TRPV receptors are mechanosensory and signal in response
to changes in the ECM due to contractile forces. TGF-β2-induces ECM reorganization
and collagen deposition that affects the cell membrane mechanical forces that are
transmitted via TRP receptors. Therefore TRPV1 receptors are highlighted as therapeutic
targets in fibrotic and metastatic conditions [94] and may be one potential target of
OLDA in this study.
A more popular potential therapeutic target in the treatment of ocular fibrotic
conditions like PVR is TRPV4. This receptor has been highlighted as a therapeutic target
in experimental studies of retinal fibrosis due to its role in mechanosensing and ECM
remodeling in other fibrotic conditions [94-96]. TRPV receptors are located at cell-matrix
adhesions and sample mechanical status of the ECM. TGF-β induces fibroblast
contraction and matrix stiffening and the contractile forces are sensed and transmitted by
TRPV [94]. The endocannabinoid AEA and its metabolite arachidonic acid are agonists
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at TRPV4 and a structurally similar N-acyl amine, N-acyl taurine, is reported to have
moderate agonist activity at TRPV4 [22]. More research is needed to highlight any
potential activity of OLDA at TRPV4.
OLDA is reported to have therapeutic potential through various mechanisms,
most prominently through its anti-inflammatory and antioxidant properties. As an antiinflammatory, OLDA acts as a stabilizer of COX-2 and is therefore thought to act as a
neuroprotective compound, due to its presence in the brain. OLDA has also been found in
human plasma suggesting peripheral activity and production [33]. GPR119 is a receptor
that has been implicated in diabetes due to its involvement in insulin secretion and
selective expression in pancreatic islet cells and in the gut. This receptor has high
sequence homology with the CB1 and CB2 receptor and OLDA is an agonist [21].
Recent research has highlighted the presence of GPR119 in the mammalian eye [97] and
therefore may be involved in the present study as well. Lastly, OLDA is reportedly an
inverse agonist at the GPR6 receptor, another GPCR with high sequence homology to
CB1 and CB2 receptors that is expressed in the CNS [19].Thus, there are many potential
receptors responsible for the modulating effects of ODLA reported here.
There is mounting evidence indicating that the ECS is an innovative target in the
treatment of fibrotic conditions. Further research will investigate how dysregulated
endocannabinoid signaling contributes to the pathophysiology of retinal fibrosis.
Moreover, it will be imperative that future studies investigate the mechanisms of action
of OLDA effects on fibrotic endpoints beyond α-SMA, and their potential in vivo to
prevent the formation and contraction of ERMs.
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LIST OF ABBREVIATIONS
2-AG

2-arachidonoyl glycerol

2-AGE

2-arachidonoyl glycerol ether

AADC

Amino acid decarboxylase

AEA

N-arachidonoyl ethanolamine

AMD

Age-related macular degeneration

BLM

Bleomycin

BrdU

Bromodeoxyuridine

CBD

Cannabidiol

CBDV

Cannabidivarin

CBG

Cannabigerol

CBN

Cannabinol

CNS

Central nervous system

COMT

Catechol-O-methyltransferase

COX-2

Cyclooxygenase 2

CYP450

Cytochrome P 450

DAGL

Diacylglycerol lipase

DR

Diabetic retinopathy
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ECM

Extracellular matrix

ECS

Endocannabinoid system

EMT

Epithelial-to-mesenchymal transition

ERM

Epiretinal membrane

FAAH

Fatty acid amide hydrolase

FAK

Focal adhesion kinase

GPCR

G protein-coupled receptor

LPI

Lysophosphatidylinositol

MAGL

Monoacylglycerol lipase

MAPK

Mitogen-activated protein kinase

NADA

N-arachidonoyl dopamine

NAPE-PLD

N-acyl phosphatidyl ethanolamine phospholipase D

OAE

O-arachidonoyl ethanolamine

OLDA

N-oleoyl dopamine

PALDA

N-palmitoyl dopamine

PDR

Proliferative diabetic retinopathy

PLD

Phospholipase D

PPAR

Peroxisome proliferator activated receptor
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PVR

Proliferative vitreoretinopathy

ROP

Retinopathy of prematurity

ROS

Reactive oxygen species

RPE

Retinal pigment epithelial

TGF-β

Transforming growth factor β

TH

Tyrosine hydroxylase

TRD

Traction retinal detachment

TRP

Transient receptor potential

TRPV

Transient receptor potential vanilloid

α-SMA

α-smooth muscle actin

Δ9-THC

Δ9-tetrahydrocannabinol

47

CURRICULUM VITAE
Lucy June Sloan
Department of Pharmacology and Toxicology
500 South Preston Street
Building A, Room 1305
Louisville, KY 40204
Email: lucy.sloan@louisville.edu
EDUCATION:
B.A., Neuroscience
Colorado College, Colorado Springs, CO
2014 - 2018
AWARDS:
University of Louisville Integrated Programs in the Biomedical Science Graduate
Fellowship
2020 – 2022
International Cannabinoid Research Symposium Travel Award
2021
Braude Foundation Award, International Cannabinoid Research Symposium
2021
PROFESSIONAL SOCIETIES:
International Cannabinoid Research Society
2020-present
Society for Neuroscience
2018-2019
PUBLICATIONS:
Aebersold, A., Duff, M., Sloan, L., and Song, Z.-H. (2021). Cannabidiol signaling in the
eye and its potential as an ocular therapeutic agent Cellular Physiology and
Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry,
and Pharmacology 55, no. S5 (2021): 1-14.
48

Nguyen, V. T., Uchida, R., Warling, A., Sloan, L. J., Saviano, M. S., Wicinski, B., ... &
Jacobs, B. (2020). Comparative neocortical neuromorphology in felids: African lion,
African leopard, and cheetah. Journal of Comparative Neurology, 528(8), 1392-1422.
ORAL PRESENTATIONS:
“Cannabinoid Signaling and Epithelial-Mesenchymal Transition”. Pharmacology &
Toxicology Seminar Series, March 2021. University of Louisville, Louisville, KY.
“CBD Inhibits Angiogenic Processes in Mouse Retinal Microvascular Endothelial Cells
(mRMVECs)”. International Cannabinoid Research Symposium. June 2021. Jerusalem,
Israel (Virtual).
CONFERENCE POSTER PRESENTATIONS:
“The effects of -acyl dopamine compounds on porcine retinal cells”.
Research!Louisville, October 2021. University of Louisville, Louisville, KY.
“Comparative morphology of gigantopyramidal neurons in primary motor cortex across
mammals”. Society for Neuroscience Annual Symposium. November 2017. Washington
D.C.
“Comparative morphology of gigantopyramidal neurons in primary motor cortex across
mammals”. Front Range Neuroscience Conference. December 2017. Fort Collins, CO.

49

